In Vivo Assessment of Astrocyte Reactivity in Patients with Progressive Supranuclear Palsy
Authors:
Open Access
- 21 May 2024
- journal article
- research article
- Published by Wiley in Annals of Neurology
- Vol. 96 (2) , 247-261
Abstract
Objective: Although astrocytic pathology is a pathological hallmark of progressive supranuclear palsy (PSP), its pathophysiological role remains unclear. This study aimed to assess astrocyte reactivity in vivo in patients with PSP. Furthermore, we investigated alterations in brain lactate levels and their relationship with astrocyte reactivity.Methods: We included 30 patients with PSP‐Richardson syndrome and 30 healthy controls; in patients, tau deposition was confirmed through 18F‐florzolotau positron emission tomography. Myo‐inositol, an astroglial marker, and lactate were quantified in the anterior cingulate cortex through magnetic resonance spectroscopy. We measured plasma biomarkers, including glial fibrillary acidic protein as another astrocytic marker. The anterior cingulate cortex was histologically assessed in postmortem samples of another 3 patients with PSP with comparable disease durations.Results: The levels of myo‐inositol and plasma glial fibrillary acidic protein were significantly higher in patients than those in healthy controls (p < 0.05); these increases were significantly associated with PSP rating scale and cognitive function scores (p < 0.05). The lactate level was high in patients, and correlated significantly with high myo‐inositol levels. Histological analysis of the anterior cingulate cortex in patients revealed reactive astrocytes, despite mild tau deposition, and no marked synaptic loss.Interpretation: We discovered high levels of astrocyte biomarkers in patients with PSP, suggesting astrocyte reactivity. The association between myo‐inositol and lactate levels suggests a link between reactive astrocytes and brain energy metabolism changes. Our results indicate that astrocyte reactivity in the anterior cingulate cortex precedes pronounced tau pathology and neurodegenerative processes in that region, and affects brain function in PSP. ANN NEUROL 2024;96:247–261Keywords
Funding Information
- Japan Society for the Promotion of Science (JP19H01041, JP21K18268)
- Niigata University
- Japan Agency for Medical Research and Development (JP19dm0207072, JP21zf0127004, JP22dk0207055, JP22dk0207063)
This publication has 61 references indexed in Scilit:
- Altered Brain Energy Metabolism Related to Astrocytes in Alzheimer's DiseaseAnnals of Neurology, 2023
- Plasma glial fibrillary acidic protein in autosomal dominant Alzheimer's disease: Associations with Aβ‐PET, neurodegeneration, and cognitionAlzheimer's & Dementia, 2022
- Amyotrophic Lateral Sclerosis with Pallidonigroluysian Degeneration: A Clinicopathological StudyAnnals of Neurology, 2019
- Magnetic resonance spectroscopy reveals abnormalities of glucose metabolism in the Alzheimer's brainAnnals of Clinical and Translational Neurology, 2018
- Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteriaMovement Disorders, 2017
- Tissue correction for GABA‐edited MRS: Considerations of voxel composition, tissue segmentation, and tissue relaxationsJournal of Magnetic Resonance Imaging, 2015
- Cerebrospinal fluid tau and phosphorylated tau protein are elevated in corticobasal syndromeMovement Disorders, 2010
- Patterns of Brain Atrophy That Differentiate Corticobasal Degeneration Syndrome From Progressive Supranuclear PalsyArchives of Neurology, 2006
- Decreased concentrations of GLUT1 and GLUT3 glucose transporters in the brains of patients with Alzheimer's diseaseAnnals of Neurology, 1994
- Positron Emission Tomography Study in Progressive Supranuclear PalsyArchives of Neurology, 1990